General Information of This Metabolic Reaction (MR) (ID: MR012792)
Formula Reactant UK-453,061 Product UK-453,061 Metabolite M17
Reactant Info Product Info
Metabolic Enzyme Cytochrome P450 3A4 (CYP3A4) DME Info
Metabolic Type Oxidation - Mono-oxidation
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR012801 UK-453,061 UK-453,061 Metabolite M1 Unclear UK-453,061 [1]
MR012802 UK-453,061 UK-453,061 Metabolite M10 Unclear UK-453,061 [1]
MR012803 UK-453,061 UK-453,061 Metabolite M12 Unclear UK-453,061 [1]
MR012794 UK-453,061 UK-453,061 Metabolite M13 Unclear UK-453,061 [1]
MR012809 UK-453,061 UK-453,061 Metabolite M15 Unclear UK-453,061 [1]
MR012810 UK-453,061 UK-453,061 Metabolite M18 Unclear UK-453,061 [1]
MR012808 UK-453,061 UK-453,061 Metabolite M19 Unclear UK-453,061 [1]
MR012796 UK-453,061 UK-453,061 Metabolite M21 Unclear UK-453,061 [1]
MR012806 UK-453,061 UK-453,061 Metabolite M3 Multi-steps Reaction - Glucuronidation; monohydroxylation UK-453,061 [1]
MR012804 UK-453,061 UK-453,061 Metabolite M4 Multi-steps Reaction - Oxidationn; glucuronidation; hydrolysis UK-453,061 [1]
MR012805 UK-453,061 UK-453,061 Metabolite M5 Unclear UK-453,061 [1]
MR012807 UK-453,061 UK-453,061 Metabolite M6 Multi-steps Reaction - Glucuronidation; monohydroxylation UK-453,061 [1]
Other MR(s) Related to The Product of This MR
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR012793 UK-453,061 Metabolite M17 UK-453,061 Metabolite M8 Multi-steps Reaction - Glucuronidation; monohydroxylation UK-453,061 [1]
References
1 Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers. Drug Metab Dispos. 2010 May;38(5):789-800.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.